- Home
- IXHL vs ALXO Comparison
IXHL vs ALXO Comparison
Compare IXHL & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IXHL
- ALXO
- Stock Information
- Founded
- IXHL 2001
- ALXO 2015
- Country
- IXHL Australia
- ALXO United States
- Employees
- IXHL N/A
- ALXO N/A
- Industry
- IXHL
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- IXHL
- ALXO Health Care
- Exchange
- IXHL Nasdaq
- ALXO Nasdaq
- Market Cap
- IXHL 20.5M
- ALXO 24.0M
- IPO Year
- IXHL N/A
- ALXO 2020
- Fundamental
- Price
- IXHL $0.21
- ALXO $0.45
- Analyst Decision
- IXHL
- ALXO Strong Buy
- Analyst Count
- IXHL 0
- ALXO 6
- Target Price
- IXHL N/A
- ALXO $3.30
- AVG Volume (30 Days)
- IXHL 35.9M
- ALXO 636.7K
- Earning Date
- IXHL 05-15-2025
- ALXO 08-07-2025
- Dividend Yield
- IXHL N/A
- ALXO N/A
- EPS Growth
- IXHL N/A
- ALXO N/A
- EPS
- IXHL N/A
- ALXO N/A
- Revenue
- IXHL $98,000.00
- ALXO N/A
- Revenue This Year
- IXHL $3,817.06
- ALXO N/A
- Revenue Next Year
- IXHL $66.67
- ALXO N/A
- P/E Ratio
- IXHL N/A
- ALXO N/A
- Revenue Growth
- IXHL N/A
- ALXO N/A
- 52 Week Low
- IXHL $0.08
- ALXO $0.40
- 52 Week High
- IXHL $3.12
- ALXO $8.78
- Technical
- Relative Strength Index (RSI)
- IXHL 46.19
- ALXO 42.78
- Support Level
- IXHL $0.20
- ALXO $0.40
- Resistance Level
- IXHL $0.23
- ALXO $0.46
- Average True Range (ATR)
- IXHL 0.02
- ALXO 0.04
- MACD
- IXHL 0.01
- ALXO -0.01
- Stochastic Oscillator
- IXHL 13.91
- ALXO 23.98
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.